Ask the doctor: For macular degeneration, which is better, Avastin or Lucentis?
I should also mention right off the bat that I am on Genentech's scientific advisory committee. Genentech developed both Avastin and Lucentis. I am also the chair of the Phase 3 clinical trial of Eylea, another drug for wet macular degeneration, which I expect will be approved by the end of 2011.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
